Luxturna was the first FDA-approved gene therapy for a disease caused by mutations in a specific gene. It helped establish Philadelphia as a biotech hub.
Luxturna was the first FDA-approved gene therapy for a disease caused by mutations in a specific gene. It helped establish Philadelphia as a biotech hub. In a 2009 photograph, Nancy Haas of Hadley, NY wipes away tears as she talks about the dramatic improvement in the vision of her son, Corey Haas, 9, since receiving the gene therapy.
for developing the first FDA-approved gene therapy for a genetic disease, prize sponsors announced Saturday. Their work created a scientific and regulatory road map for gene therapies, paving the way for more than a dozen similar approvals to follow.The awardees — Jean Bennett, Katherine High, and Albert Maguire — were receiving the award on Saturday evening at a ceremony in Los Angeles known as theLeber congenital amaurosis. The genetic disease causes degeneration of the retina, a layer of cells within the eye that detects light.By delivering a functional copy of the affected gene to patients’ eyes, the scientists found they could improve vision.Penn’s Carl June splits a $3 million Breakthrough Prize for pioneering the cancer treatment CAR-T into the eye. And High, then researching hemophilia at Children’s Hospital of Philadelphia and Penn, knew how to advanceTheir discovery not only has advanced treatment for retinal disorders, but also “charts the path” for new gene therapies, said Huda Zoghbi,Luxturna does not completely restore vision, but it can change patients’ lives by reversing some vision loss and slowing the progression of the disease. Its approval helped bolster the reputation of Spark Therapeutics, which spun out of CHOP in 2013, as a pioneering gene therapy company, and establish Philadelphia as a biotech hub.Bennett recalls how patients and families described the therapy changing their lives at an FDA open session meeting when Luxturna was seeking regulatory approvals. “It still makes me well up with tears thinking about some of the stories people told,” said Bennett, who described herself as “thrilled and honored, and humbled,” to share the prize.She was interested in applying her Ph.D. in zoology and cell and developmental biology to treat disease at its genetic origins, a concept not yet tested in humans. He had become interested in the retina, an area of the eye that he compared to a camera film that converts light into pictures via signals to the brain. Knowing that many retinal diseases are genetic, Maguire thought cloning a functional copy of a gene and putting it into the affected tissue could treat defects.At the time, few genes for the retinal diseases had even been identified. Starting in the early 1990s, they spent about a decade developing all of the technical aspects of their therapy, including figuring out how to deliver the gene and measure its function.Leber congenital amaurosisThe duo designed their therapy using what is called a “vector,” which functions much like a delivery truck carrying packages. In their case, their vector was a “gutted” virus designed to carry a functional copy of the mutated RPE65 gene, Maguire said.In the late 1990s, they learned collaborators had obtained dogs with the same mutated gene that humans with the disease had.study. In July 2000, they injected the therapy into one eye each in three of the dogs, and left a fourth as an untreated control for comparison.The dogs were running around without bumping into things, “which they couldn’t do beforehand,” Bennett said. They were even stealing kibble from other dogs who couldn’t see the food bowl nearly as well. As High’s first trials on a gene therapy for hemophilia were starting to show success, a patient’s death in a separate gene therapy trial at Penn roiled the field. Jesse Gelsinger’s death in 1999, the first from a gene therapy clinical trial, coupled with the development of leukemia in several patients participating in separate trials, scared investors away from gene therapy, to the point that the California-based company High relied on to manufacture her vectors could not raise money. “All the news about gene therapy was bad. Didn’t matter whether you were reading scientific journals or the Wall Street Journal,” High said.to Steven Altschuler, who was the CEO of CHOP at the time. If they couldn’t start producing those vectors in the hospital, she was going to have to stop her gene therapy research. A week later, he said he would find the resources for vector production in the hospital — but under one condition.Her mind quickly went to Bennett, a longtime colleague. Their children were even in school together.Early safety data persuaded regulators to let them include children, who stood to benefit the most, given the disease’s degenerative nature. It was the first time children who did not have a fatal disease were involved in gene therapy trials, High noted.effects, they developed a mobility test to measure “functional vision” in daily living. It consisted of a mobility course, which had a series of guiding arrows on the floor and obstacles like steps and a door.They found that patients in the intervention group were able to pass the course at lower light levels, with a quicker pace, and maintain that progress over a year. In 2017, they received approval from the Food and Drug Administration for the therapy marketed as Luxturna.Today, most of the roughly 1,000 people estimated to be eligible in the U.S. have been treated, and the therapy has since moved into overseas markets.Luxturna was listed at $425,000 per eye when it was approved. Swiss pharmaceutical giantDozens of retinal gene therapy trials targeting different conditions are underway worldwide.{"ENV":"VW9nQ10cXUx+cAgEXAxaTXxddEB0MWBCa1AMCg==","CONTENT_BASE_PROD":"UHBFB1oifAFVWkFcWj5sA3xzaEBjMnAHf2BkQHcMYAd8c3xPYDJzX3xgdEBjDHNdf3NnWnQidE9oXXAHYDJkQnxjZE9jDGddf3NZW2MhYE98cGQHYyJWBX9deE13C29Za11jW3cxb14=","ARC_ACCESS_TOKEN_PROD":"VHBWBGAIc0VVXWtdYyJaQmtjcE93InRNf11SBncyYE9rXWNcdCFkQn5jcAV0MXBNfGNnXHQidE9rY3xOdwx0QmtaaAV0VHxPfHNnX3QyfE1oXXgGYwtsBnxNe190HGRNf2BkB3cydEJ8WmROdDJeT2tweEB0Ml1Zf3N0BnQxYAR/WmRNdBxwQmhgaE13InNZf2NzXHQiZEJoTVVcdDFsQmhjcE9jDF1dfFpkBGMyXVl/cGtfYDJnWWtjcAR0Mn9YaGB4BnQcXk1oBWgFYwxSCA==","GRAPHQL_KEY":"f01VAXYxe1lQXVJOYAhwA39NZAdjMntff11oBHchYE18TXgHdDJRX3xaeAdgMm9dfGNrWmAMbE1rY3xNYzJwT2hdfAd0DH9ffGB0BmMiY1hrXVYGYDFsTHxjZAZgVHwHf2NaQGM3CAg=","GATEWAY_URL":"UAV/RlgMc1lTcABaXDFgA39zUkB3InQFfHN8B2Acc1h8c2RPdxxwBWtaZE92MnNefF1aBmAccAR/c2BPYwtgQnxjWgZgC2wEfE1VW3QhY1xrY2dadAt8BQ==","GATEWAY_SLS_URL":"fHN7R3cLQgF8WmsBXAhnWn5dd113MmBCf01nWnQycAV8XWdedDF4Qn5wa1x0IlJNa2NVX3QiZE1/XWBNdDJvXH9zYAV3MX9Yf114A2MLb1l8cHtaYDFzWWhADAo=","FEEDS_URL":"UFpdAncIXQZUc2dfXS5wA39za1t2MnBNf2NWQHcyd1h8Y2gHdCJwAXxzeEB0InBNfFpgQHQyZAR/c2hAd1RsBmhdc1t3HHwFfF14T3cxYAR8c2AFdFRvX2tdaE13HFZCfF1oTmMxYE1rXWtadCFjXn9jZAo=","RESIZER_KEY":"UmNoBGAMfwNQcElAXQh0A39zZARjImdYfHNwTWAyZEJ8TXxNYBx7WHxjcE9gDHwAf3NSBXcyY15oXXxPdDFgBHxdYEB0DG9ea11STWAMZAVoWmRNdCFwTGtjVk53IWAEa11aT3QnCAg=","GOOGLEANALYTICS_ID":"a1pFB10icwRVWVledgxgT39wfAdgHHgFf2B0B3QMZ11/c2gGdiJkAHxdUk5jAQgI","TWITTER_API_TOKEN":"VW93QGBVd0FUb1VdXAxaTGtdfE50C2RPaF13XmMxYE1oTXdbdAtwTWhNeAZjDHBPfHN4TXQLb1lrc3BAdAxZWXxzcAd0VHxPfwVrXWMxeE18XXRNdBxRWX9NYE50MllYa3N3XmMMY1loTXgDYzFzWHxwZ1tjMWBNfGBoB2Mid1loXXwDdDJSTX9gaANjMWdZfFpoBHQheE1+cGAFYwtzXnxafAN0IXNff2BnXGMMVkJrWmgDYyF7WGhafE9gVH9ZfFpgBGBUf1h8cGRAYzJgQn5gaAJjMWxNfE1wQGBUc19/BWRAYzJRWWhgZAdjDGRNaGBrX2BUY1loYHQHYzJjXn9aZ1t0In9ffHBgBmMMf15oWmNdYBxRXmtzc1pjIXNea3B8B2Mhc15rYGAGYyJdWXxgfAJgHHdea2YMCg==","GOOGLE_CLIENT_EMAIL":"UGBFWGAxQUNQBFkHWD5wA3xzUkBjMnddf3BoB2AcdE18Y3hAYyJzX3xjVk9jInRMfFp4T3Qcc1hrY1pPdjFgTHxwZAdgMnwGfHB3W2Acf158XXRNdBx8TXxdY1t0In9cfAVjW3QLb15rYH9adiFsTXxdZ1tgVGBNfHN/WncLYARrWmNbYwx4AWtjY11gDHtda113XXRUb1h8XXxOYFR4AGtwdAo=","GOOGLE_PRIVATE_KEY":"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","BLUECONIC_ENDPOINT":"UnAJBGALe0VrTV0GXCJaQn9NcEB3MlIFaE1nXnQxcEJ+Y2NddDFkQmtaaEB0MXwGf11kB2MycE1oYGQFdyFzWGtwa1p0VGdZaE1wA3QMVk98WmgDYzFzXH9jY19jDGQI","BLUECONIC_STORE_ID":"fAVaAlwLDANTb0FBYzJsA39jeEB3DGNdf3BoQGAyeAB/YHhPdyJgBHxjfEBgDGNfa2BoBHYieAF8WnxAYAxjXXxzVk9gHHBPfwVkBHQMfAV/TWhOYAx7XXxNWk90HHwHfF1wTXccbAdoWn9bdDJvXw==","BLUECONIC_KEY":"UloEAndUDAFoXXgFY1RaA3xzfEB0Mnddf2NWB3YydE98cHwGYycICA==","BLUECONIC_SECRET":"fm9BAl0xXQdSBWNFYFQBA39aYE5gMntcfHN4QGMidEx8c2gGYwx7XnxjWk50C3wBf2NoTmMMfAR8cHxAYyFvXXxdeE92MnNca2NnX2ALbAZ8XWROdyFjX3wFeAZ0MnQGa2NwQHcnCAg=","AMP_AUTH_BASE_URL":"VG9VXHRVf19+YAQEWiF4A3xje1p3HHNff2NgQGAcc1h/c1ZAdjJkT3xgf1t0DHRMfE1kBnRUfAZ8c1pPdDJ3X2tgZEBgMngBf2BjWnQcd19rYGAHdiFgTGtgfAVgVGAEfE13W3cxYAZrWndbdAtgT2hgaE1jDHRNaGNzWncxZ1hrc3daYAEICA==","AUTH0_DOMAIN":"UHB/R2ALBQd+YGddWyFCA3xzaEB3DHdcf3B8B3ciYE1/c3xAYDJzXmtgaE9gDHNYa2NoT2MMc1h8Y1YHYDJkTQ==","AUTH0_CLIENTID":"U3NnXGM+XUJTWXdYWyFwA3xzYAdjDGBNfE10T2MMfAd8c3AHYzFjXHwFYEB0IndffGN4BmAMY118XXtadjJ3WXxjaE13HGAEfHN8TmALfExrY2hPdAx8AWtdUgZ0InRCfHBkT3Y3CAg=","PIANO_ID":"VWB7RF0xDFhTXX9bdAxeA3xNUkB3Mn9YfGNkTmMMdAF8cHgGdDJzXX8FZAo=","MIXED_CONTENT":"U11jTmMIY0BSWXdOd1R8A3xzcAZ0MnBCf3NWB3QydEJ8c1JAdDJ3XX9gfE9gDHNffGB3WncMcARrXVJPYBxkBXxwZEB2Mndff2B/W2ALf198c1YGYAx4T3xNYE10C2AEa2N7X3RUYAA=","VIAFOURA_SITE_UUID":"VWABAnYhWgdTcElAXDFkA3xjfAZ2MndYfHN0QGMMY15/Y3AGdzJzXnxNdAZgMngEa2B4BGMiUV98WnQEYyJjXHxdWk12InRMfFp8TXcifAR/TXgFYBx8Bn9NZ1tjDHgBfF1gTnYyeAZ8XVpNdiJsTQ==","GOOGLE_CLIENT_ID":"VVpgAnYhYARUf2MCXCEFA3xjVkB0MmNcfGNoB3QMY1x8Y3RAdiJ3X3xjZEB3VGwFf2B3XnYhfAB8Y2gHYDJ0BHxwdEB3Intff2N/WmMhY19oXXteYAx8TGhdfE13MW9ZfF1ZWnQye1h8WnxNdDFwTX9gd1t0IX9Za11rWmAcc19rY3daYAxwTGhNc153DF4Aa1p0AmAyc1hrc2ROYwxwTWgFa1x3DHQBf3B0A3YidAd+YGRAdyJ0QnxzdEBjDHNZfHN0T2AMWVl/cGhPdiJkAQ==","AUTH0_BASE_URL":"Ul1zQndUc0J/TVVDXAxaBGtjZAR0InQEa2N3XXcheAV8TWNedDJ4Qn5jYAZ3MXhMaGB4BmMyYAVoWntcdyFvWWhNcAZ0DHNcaE17WndUZE1rc3NadxxwBnxaZAdjMX9Zf1p0B2MMWVx8QAwK","CHARTBEAT_DOMAIN":"f01kBGMhTUZ/BWROXCJsA39jWgZ0ImAEf3B0B3cyd1x/cGBAYDJnX2taeAd0MmRC","G_OPTIMIZE_CONTAINER_ID":"VVlBBXQIcE9ob1ZPdAxaTHxNfAd3IXxCfnNVXncMcE98c2NedwxWBGhjfAM=","G_TAG_MANAGER_CONTAINER_ID":"fwVWBVwhUU1ob3sFXQxeA39dfE50ImwGfFpkBHYyf15/Y3BOdDJ8AHxdfAo=","SF_CLIENT_SECRET":"VFoEBWMMewRScGNDdBxaT35zZ190HGAEaE1kBnchbAV+Y2QDdAx4Bnxjf1p3MnRNfnNkA3cMcE9/Y3hAdFR8TGtdUkB3MnxPfnN/XHQLbAZrXXQHdDJ0T3xNYE53DHRMaGN/XHQycE9+c2dfdAxwBX9jc1x0Il4HfmN4BHQcfE1oTXADYAtgQn9ddEB0InRCfnNnWnQyVk1+cGdbdDJgBH5jc110IWxNfE10BHcif158Y3BNYwx4TX5mDAo=","G_RECAPCHA_V3_KEY":"UGN3BltVWU1Tc1lGdzFCA3xNWgRgDHdffHBgBGMMcAd8TWgFYDJ0AX9NYEB2MngFfGNaTXYieE98WmRPdyJ8BH9jVkB2ImdffF1nW2Mxf1xrWmBPdxxwAXxaZAZjMmNcfHBoBWAyc118Y2gFdFRkBn9wd1pjMnRNfE14Cg==","G_RECAPCHA_V2_KEY":"VXB7WGMhQVxVBQQGdyFCA39zUk9gHHxPf2NSQHQMc11rXWRPdDFsBX9jZE9jDHQAf01aQGALYAR8cGRAdiJ/XWtgYE90HGdZfE1kTmAcf1h8TWtadCJ3XXwFYAd3MndefGNwBWALb198XVZNYAxwAH9ge1tjInBMfF1aCg==","GROWTHBOOK_CLIENT_KEY":"VVprA3cLDF1/TVUDdyFkA39wfE9gMngFf2N8BnYicE1/BWgHYwx8AX9zeAZ2MndZf3B4TWAcd1h8Y2hPdwt/WQ==","SOPHI_HOSTNAME":"fmBaQFghYE1Ub14HYy5gA39jUkBgHGBMf3NoB2AcYAd8c3xPdzJnXWtjUkB0DGdZa2B8B2MicAZrY3AK","HTL_SCRIPT":"U29dXnYhc0RTBUYFY1QBA3xgYE9gDGdef2B8TnQcdEJ8YGhPdCJkBH9wdE93DHABfE1aBnciZ118Y3tbYzJgAWtgaAd3MmNZa2BjW3chb1lrY1IHdBx8BnwFeAZ0DHwAaFprW2AxY1l8WntadCFjXn9dd1p0MWxMa1poTXYiUVx8c2NdYwx7WWtzXV10C3BC","LIVEBLOG_WS_SERVER":"UmBSAlwLbwBrWVZAdDJaTWtdcE53MXwEf3NjWnQxYE1oTXQEdyFjXHxdcAV0MndcaE10BHQycEJ/Y3QEdCJRXH9NY1t0VGAEaGNwBXQMXVlrYGQDYzJSCA==","SOPHI_SCRIPT":"Uk1dXWNUAFpQWXNNdwtaA3xzfAZgDGdff2BkQGAyf19/Y2gHYyJnWH9NfAZ0InhNf2NoBncMcAd8Y3hPdjJwTWtdXVpgMX9dfF10B2BUfE98YGNaYwtjWWtgeE53IWxCfE1jX3dUb15rWn9fYAtvXXwFYE50VGAGa2NkTncxbAFoY39dYDJwBn5jVk13MWwAa11dWnQyeAV8WmNcdAxZWGhNa1xjDF4Ha1poCg==","STATS_WIDGET_CLIENT_ID":"fnNVA1wxAFlSWggCdwt8A39zWgZ2IndcfGNoB3Yic1l8YHxAdCJzXn9zZE93DGRCfHNgQHQidAF8YHRPdxx3XXxjf1p2Mnde","_id":"0d5ac1483c85ef08162beb00785d4bd9ff12fbc6d72a4b6bd02efb512fdf1f95"}
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
LVL UP Expo 2026: Everything You Need To Know About The ConventionBritt Rivera is a writer, editor, and events producer with a bachelor of arts in English from Binghamton Universtiy where she also studied cinema after falling in love with movies at a young age thanks to her father. She has written for websites including Fandom, Remezcla, Cutlress, and The Marvel Report.
Read more »
How much are tickets to see Vanessa Carlton on her 2026 'Veils Tour'?The three-time Grammy nominee will let loose from the piano bench at NYC’s City Winery on May 15-16.
Read more »
Comet R3 PanSTARRS at PerihelionWe’re one comet down, and one to go for spring season 2026. We recently wrote about prospects for sungrazer C/2026 A1 MAPS and comet C/2025 R3 Pan-STARRS in April 2026.
Read more »
Coachella 2026: These are the roads closed around the festivalAll the road closures, detours and transportation adjustments in place for Weekend 2 of the Coachella festival in Indio.
Read more »
Johnny Gaudreau, Carli Lloyd, and Hugh Douglas highlight the 2026 Philly Sports Hall of Fame classThe ceremony honoring the best in sports from the Greater Philadelphia Region will take place on Thursday, November 5, at Live! Casino and Hotel in South Philadelphia.
Read more »
Zara Larsson’s ‘Midnight Sun’ World & ‘Stateside’ Magic with PinkPantheressBillboard Women in Music 2026 Breakthrough honoree, Zara Larsson, opens up about her ‘Midnight Sun’ era.
Read more »